期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 496, 期 2, 页码 541-550出版社
ELSEVIER
DOI: 10.1016/j.ijpharm.2015.10.055
关键词
Additive manufacturing; Tissue engineering; Regenerative medicine; Bone regeneration; Controlled drug release
资金
- TUM University Foundation
- Spanish Xunta de Galicia
- Ministerio de Economia y Competitividad of Spain [SAF2014-52632-R]
- FEDER
The adoption of additive manufacturing in tissue engineering and regenerative medicine (TERM) strategies greatly relies on the development of novel 3D printable materials with advanced properties. In this work we have developed a material for bone TERM applications with tunable bioerosion rate and dexamethasone release profile which can be further employed in fused deposition modelling (the most common and accessible 3D printing technology in the market). The developed material consisted of a blend of poly-e-caprolactone (PCL) and poloxamine (Tetronic1) and was processed into a ready-to-use filament form by means of a simplified melt-based methodology, therefore eliminating the utilization of solvents. 3D scaffolds composed of various blend formulations were additively manufactured and analyzed revealing blend ratio-specific degradation rates and dexamethasone release profiles. Furthermore, in vitro culture studies revealed a similar blend ratio-specific trend concerning the osteoinductive activity of the fabricated scaffolds when these were seeded and cultured with human mesenchymal stem cells. The developed material enables to specifically address different regenerative requirements found in various tissue defects. The versatility of such strategy is further increased by the ability of additive manufacturing to accurately fabricate implants matching any given defect geometry. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据